Evonik expands in pharma in Germany

Evonik, which is one of the world’s largest pharmaceutical CDMOs, has announced the €25 million first stage of a long-term programme to expand API and advanced intermediates capacity at its sites in Dossenheim and Hanau, Germany. This should be completed by mid-2021 and the whole project should be finalised prior to 2024.

This came in response to growing demand for European-based manufacturing sites to ensure supply during the Covid-19 pandemic and was also done to broaden the company’s ability to support highly complex projects. These include oncological, anti-viral and other specialised drug products, which typically require a range of advanced technologies including continuous processing, highly pure PEGs and mPEGs, catalysis and cryogenic chemistry.